Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zynex, Inc. and reminds investors of the upcoming deadline to seek the role of lead plaintiff in a federal securities class action against the company [4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is a national securities law firm that has recovered hundreds of millions of dollars for investors since its founding in 1995 [5]. - The firm is encouraging investors who suffered losses in Zynex between February 25, 2021, and December 15, 2025, to discuss their legal rights [1]. - There is a deadline of April 21, 2026, for investors to seek the role of lead plaintiff in the class action lawsuit against Zynex [4]. Group 2: Company Conduct and Allegations - The complaint alleges that Zynex and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts [6]. - The investigation is also open to anyone with information regarding Zynex's conduct, including whistleblowers and former employees [9].

Summary of VistaGen Therapeutics Conference Call Company Overview - **Company**: VistaGen Therapeutics (NasdaqCM: VTGN) - **Product**: Fasedienol, a rapid onset, non-systemic, intranasal product candidate for the acute treatment of social anxiety disorder [2][3] Key Points and Arguments Fasedienol Development - Fasedienol is under development with Fast Track designation for treating social anxiety disorder, which affects individuals from adolescence onward [2] - The PALISADE program consists of multiple phase 3 studies, including PALISADE-2 (positive outcome), PALISADE-3 (did not separate), and ongoing PALISADE-4, expected to read out in the first half of the year [3][4] - The treatment effect of fasedienol has been consistent across studies, while the placebo effect has shown variability, prompting a focus on operational execution and placebo mitigation strategies for PALISADE-4 [4][5] Data Analysis and AI Utilization - Advanced analytics, including AI and machine learning, are being leveraged to analyze historical data from PALISADE-1 to PALISADE-3 to identify patterns that may explain variability in treatment responses [5][7] - The company is exploring vocal biomarkers and behavioral indicators of anxiety to inform the statistical analysis plan for PALISADE-4 [5][32] Study Execution and Adjustments - Experience at the site level is crucial; sites with more experience conducting the study may yield better outcomes [11] - Adjustments to the study design and execution based on learnings from PALISADE-3 are being implemented in PALISADE-4 to control variability and enhance data consistency [33][34] Regulatory Pathway and Confidence - The company is confident that PALISADE-2 is a registration-worthy study, which, along with a successful PALISADE-4, could support a New Drug Application (NDA) submission [27][28] - The totality of data, including real-world evidence and safety databases, will be presented to regulatory agencies to advocate for the approval of fasedienol as the first acute treatment for social anxiety disorder [24][25] Pipeline and Future Developments - VistaGen has five assets in its pipeline, all having achieved clinical success in at least Phase IIa studies, including a depression program and a hot flashes program expected to clear IND by the end of the first half of the year [44] - The company has a cash runway extending into 2027, providing financial stability for ongoing and future studies [46] Additional Important Information - The company emphasizes the importance of both controlled clinical trials and real-world data to understand the drug's impact on daily life and patient confidence [43] - The secondary endpoints, including Clinical Global Impression (CGI) and Patient Global Impression of Change (PGIC), are important for assessing treatment efficacy, although they are not critical for labeling if approved [40][42]

Core Viewpoint - Faruqi & Faruqi, LLP is reminding investors of Vistagen Therapeutics about the deadline for a securities class action lawsuit, which is set for March 16, 2026, and is encouraging affected investors to discuss their legal options [1][2][3]. Group 1: Class Action Details - The class action lawsuit is based on allegations that Vistagen and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts regarding its Phase 3 PALISADE-3 trial of fasedienol, aimed at treating social anxiety disorder [4]. - The lawsuit pertains to investors who purchased or acquired Vistagen securities between April 1, 2024, and December 16, 2025 [1][2]. Group 2: Stock Performance Impact - Following the announcement of the PALISADE-3 trial results on December 17, 2025, Vistagen's stock price dropped by $3.50, or 80.27%, closing at $0.86, as the study did not meet its primary efficacy endpoint [5]. Group 3: Legal Process and Participation - The lead plaintiff in the class action will be the investor with the largest financial interest who is also typical of the class members, and any member of the class can move to serve as lead plaintiff or remain an absent class member [6]. - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [7].

Group 1 - The Rosen Law Firm is reminding purchasers of Vistagen Therapeutics, Inc. common stock between April 1, 2024, and December 16, 2025, of the March 16, 2026, lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased Vistagen common stock during the specified period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court by March 16, 2026, to serve as lead plaintiff [3] Group 2 - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is in development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6] - Defendants made positive assertions about fasedienol's future trial success based on prior positive results from the PALISADE-2 clinical trial, which allegedly misled investors [5] - The lawsuit claims that when the true details about the trial were revealed, investors suffered damages [6] Group 3 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [4]

Core Viewpoint - Rosen Law Firm is reminding purchasers of Vistagen Therapeutics, Inc. common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to the company's alleged misleading statements regarding its drug fasedienol [1][3]. Group 1: Class Action Details - Investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable ranking by ISS Securities Class Action Services [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided investors with overly positive information regarding its drug fasedienol, which is in development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - The misleading statements made by the defendants led to investor damages when the true details about the trial were revealed [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Vistagen and its executives failed to disclose material adverse facts regarding the efficacy of fasedienol in clinical trials [4]. Group 2: Trial Results and Market Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, resulting in a significant stock price drop of $3.50, or 80.27%, closing at $0.86 [5]. - The study's failure to demonstrate statistically significant improvement in anxiety reduction compared to placebo has raised concerns among investors [5]. Group 3: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational footprint [3]. Group 4: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Background - The lawsuit alleges that Vistagen's defendants provided misleading information regarding the development and commercialization of its drug fasedienol, which is intended for treating social anxiety disorder [5]. - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth was revealed [6].

Group 1 - A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. alleging false and misleading statements regarding the risks of failure associated with its Phase 3 PALISADE-3 trial study of fasedienol [1] - The lawsuit targets investors who purchased Vistagen shares between April 1, 2024, and December 16, 2025, and experienced significant losses [2] - The deadline to request to be appointed as lead plaintiff in the case is March 16, 2026 [3]

Core Viewpoint - Vistagen Therapeutics is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the efficacy of its drug fasedienol, leading to significant financial losses for investors [1][1]. Group 1: Legal Action and Allegations - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics and has set a deadline of March 16, 2026, for investors to seek the role of lead plaintiff in the class action [1]. - The complaint alleges that Vistagen and its executives violated federal securities laws by making false assertions about the likelihood of success for fasedienol based on prior clinical trial results, which misled investors [1][1]. - The lawsuit follows the announcement on December 17, 2025, that the PALISADE-3 clinical trial for fasedienol failed to meet its primary efficacy endpoint, resulting in an over 81% drop in the stock price to $0.88 per share [1][1]. Group 2: Investor Information - Investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, are encouraged to contact Faruqi & Faruqi for discussions regarding their legal rights [1]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995, indicating its capability in handling such cases [1].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 16, 2026 [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][7]. - To serve as lead plaintiff, individuals must file a motion with the Court by March 16, 2026, representing the interests of other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Background - The lawsuit alleges that Vistagen's defendants provided misleading information regarding the development and commercialization of its drug fasedienol, which is intended for treating social anxiety disorder [5]. - Defendants reportedly made overly positive statements about the drug's trial success while concealing adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth was revealed [6].